Beacon Investment Advisory Services Lowers stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Beacon Investment Advisory Services reduced its stake in Gilead Sciences by 2.11% during the most recent quarter end. The investment management company now holds a total of 16,447 shares of Gilead Sciences which is valued at $1,360,167 after selling 355 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on May 9, 2016.Gilead Sciences makes up approximately 0.60% of Beacon Investment Advisory Services’s portfolio.

Other Hedge Funds, Including , Sva Plumb Wealth Management boosted its stake in GILD in the latest quarter, The investment management firm added 172 additional shares and now holds a total of 2,859 shares of Gilead Sciences which is valued at $236,439. Gilead Sciences makes up approx 0.04% of Sva Plumb Wealth Management’s portfolio.Tiaa Cref Investment Management boosted its stake in GILD in the latest quarter, The investment management firm added 166,053 additional shares and now holds a total of 11,861,160 shares of Gilead Sciences which is valued at $1,004,403,029. Gilead Sciences makes up approx 0.76% of Tiaa Cref Investment Management’s portfolio.State Treasurer State Of Michigan boosted its stake in GILD in the latest quarter, The investment management firm added 327,600 additional shares and now holds a total of 3,380,612 shares of Gilead Sciences which is valued at $286,270,224. Gilead Sciences makes up approx 2.28% of State Treasurer State Of Michigan’s portfolio.Icm Asset Management Incwa reduced its stake in GILD by selling 630 shares or 7.99% in the most recent quarter. The Hedge Fund company now holds 7,250 shares of GILD which is valued at $613,930. Gilead Sciences makes up approx 0.96% of Icm Asset Management Incwa’s portfolio.Quadrant Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 1,379 additional shares and now holds a total of 29,825 shares of Gilead Sciences which is valued at $2,630,863. Gilead Sciences makes up approx 2.20% of Quadrant Capital Management’s portfolio.

Gilead Sciences closed down -0.06 points or -0.07% at $82.7 with 83,32,857 shares getting traded on Friday. Post opening the session at $82.66, the shares hit an intraday low of $82.41 and an intraday high of $83.87 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.